On April 12, 2024, T2 Biosystems, a medical device company, was the subject of a Schedule 13G filing with the SEC, indicating a change in ownership. The filing revealed that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a U.S. citizen, collectively reported beneficial ownership of 755,000 shares of T2 Biosystems' common stock, representing 4.3% of the company's class of securities. The shares reported in the filing are based on 17,479,954 shares outstanding as per T2 Biosystems' latest quarterly report filed on August 8, 2024. The filing, which was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of T2 Biosystems, nor is it connected with any transaction with such purpose or effect.

On April 12, 2024, T2 Biosystems, a medical device company, was the subject of a Schedule 13G filing with the SEC, indicating a change in ownership. The filing revealed that New Dimensions Trading Ltd., based in the Cayman Islands, and Jacob Safier, a U.S. citizen, collectively reported beneficial ownership of 755,000 shares of T2 Biosystems' common stock, representing 4.3% of the company's class of securities. The shares reported in the filing are based on 17,479,954 shares outstanding as per T2 Biosystems' latest quarterly report filed on August 8, 2024. The filing, which was signed by Chana Edelstein, Director of New Dimensions Trading Ltd., and Jacob Safier, asserts that the acquisition of the shares is not for the purpose of changing or influencing the control of T2 Biosystems, nor is it connected with any transaction with such purpose or effect.